Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): A randomised, open-label, blinded-endpoints trial

The Lancet

Volumn 379, Issue 9826, 2012, Pages 1613-1620

  Kobayashi, Tohru ^a   Saji, Tsutomu ^b   Otani, Tetsuya ^c   Takeuchi, Kazuo ^d   Nakamura, Tetsuya ^e   Arakawa, Hirokazu ^a   Kato, Taichi ^f   Hara, Toshiro ^g   Hamaoka, Kenji ^h   Ogawa, Shunichi ⁱ   Miura, Masaru ^j   Nomura, Yuichi ^k   Fuse, Shigeto ^l   Ichida, Fukiko ^m   Seki, Mitsuru ⁿ   Fukazawa, Ryuji ^i,o   Ogawa, Chitose ^p   Furuno, Kenji ^q   Tokunaga, Hirohide ^r   Takatsuki, Shinichi ^b   Hara, Shinya ^s   Morikawa, Akihiro ^a   more..

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

^c NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^d SAITAMA UNIVERSITY   (Japan)

^e GUNMA UNIVERSITY HOSPITAL   (Japan)

^f NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g KYUSHU UNIVERSITY   (Japan)

^h KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

ⁱ NIPPON MEDICAL SCHOOL   (Japan)

^j TOKYO METROPOLITAN CHILDREN'S MEDICAL CENTER   (Japan)

^k KAGOSHIMA UNIVERSITY   (Japan)

^l Sapporo Medical Center   (Japan)

^m UNIVERSITY OF TOYAMA   (Japan)

ⁿ Gumna Children S Medical Center   (Japan)

^o NIPPON MEDICAL SCHOOL TAMA NAGAYAMA HOSPITAL   (Japan)

^p ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^q FUKUOKA HIGASHI MEDICAL CENTER   (Japan)

^r Nagoya Memorial Hospital   (Japan)

^s TOYOTA MEMORIAL HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; IMMUNOGLOBULIN; PREDNISOLONE; SODIUM;

ADOLESCENT; ADULT; CHILD; CHOLESTEROL BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HUMAN; JAPAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOCUTANEOUS LYMPH NODE SYNDROME; MULTICENTER STUDY; NEUTROPENIA; NONOCLUSIVE THROMBUS; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHOOL CHILD; SIDE EFFECT; SODIUM BLOOD LEVEL; THROMBOCYTE COUNT; THROMBUS; TREATMENT DURATION;

EID: 84862797088     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61930-2     Document Type: Article

References (33)

1. Burns JC, Glode MP. Kawasaki syndrome. Lancet 2004; 364: 533-44.
2. Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984; 2: 1055-58.
3. Newburger JW, Takahashi M, Burns JC, et al. Treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315: 341-47.
4. Newburger JW, Takahashi M, Beiser AS, et al. Single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324: 1633-39.
5. Nakamura Y, Yashiro M, Uehara R, et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2007-2008 nationwide survey. J Epidemiol 2010; 20: 302-07.
6. Uehara R, Belay ED, Maddox RA, et al. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. Pediatr Infect Dis J 2008; 27: 155-60.
7. Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 2003; 24: 145-48.
8. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. Pediatr Infect Dis J 1998; 17: 1144-48.
9. Kato H, Koike S, Yokoyama T. Kawasaki disease: Effect of treatment on coronary artery involvement. Pediatrics 1979; 63: 175-79.
10. Shinohara M, Sone K, Tomomasa T, Morikawa A. Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr 1999; 135: 465-69.
11. Wooditch AC, Aronoff SC. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children. Pediatrics 2005; 116: 989-95.
12. Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007; 356: 663-75.
13. Inoue Y, Okada Y, Shinohara M, et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr 2006; 149: 336-41.
14. Burns JC. Revisiting steroids in the primary treatment of acute Kawasaki disease. J Pediatr 2006; 149: 291-92.
15. Kobayashi T, Inoue Y, Otani T, et al. Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy for Kawasaki disease. Pediatr Infect Dis J 2009; 28: 498-502.
16. Ayusawa M, Sonobe T, Uemura S, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int 2005; 47: 232-34.
17. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006; 113: 2606-12.
18. Saji T, Sonobe T, Uemura S, et al. Guideline of acute phase therapy for Kawasaki disease. J Japan Pediatr Soc 2003; 107: 1713-15 (in Japanese).
19. Research Committee on Kawasaki Disease. Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Tokyo, Japan: Ministry of Health and Welfare, 1984 (in Japanese).
20. Fuse S, Morii M, Ooyanagi R, Kuruiwa Y, Hotsubo T, Mori T. Generation of coronary arterial inner diameter standards by echocardiography using the LMS method in children. J Japan Pediatr Soc 2009; 113: 928-34 (in Japanese).
21. Lan K, DeMets L. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-63.
22. Sundel RP, Baker AL, Fulton DR, Newburger JW. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr 2003; 142: 611-16.
23. Kijima Y, Kamiya T, Suzuki A, Hirose O, Manabe H. A trial procedure to prevent aneurysm formation of the coronary arteries by steroid pulse therapy in Kawasaki disease. Jpn Circ J 1982; 46: 1239-42.
24. Zhu BH, Lv HT, Sun L, et al. A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease. Eur J Pediatr 2011; published online Nov 5. DOI:10.1007/s00431-011-1585-4.
25. Rowley AH, Eckerley CA, Jack HM, et al. IgA plasma cells in vascular tissue of patients with Kawasaki disease. J Immunol 1997; 159: 5946-55.
26. Brown TJ, Crawford SE, Cornwall MI, et al. CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. J Infect Dis 2001; 184: 940-43.
27. Okada Y, Shinohara M, Kobayashi T, et al. Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children. J Pediatr 2003; 143: 363-67.
28. Sinha A, Bagga A. Pulse steroid therapy. Indian J Pediatr 2008; 75: 1057-66.
29. Miura M, Ohki H, Yoshiba S, et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Arch Dis Child 2005; 90: 1096-97.
30. Pyne D, Ehrenstein M, Moris V. The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic disease. Rheumatology 2002; 41: 367-74.
31. Okada K, Hara J, Maki I, et al. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Eur J Pediatr 2009; 168: 181-85.
32. Seki M, Kobayashi T, Kobayashi T, et al. External validation of a risk score to predict intravenous immunoglobulin resistance in patients with Kawasaki disease. Pediatr Infect Dis J 2011; 30: 145-47.
33. Sleeper LA, Minich LL, McCrindle BM, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr 2011; 158: 831-35.